Is Preeclampsia a Risk Factor for Postpartum Psychiatric Illness?
Most, but not all, studies show an association between preeclampsia and increased risk for postpartum psychiatric illness.
Most, but not all, studies show an association between preeclampsia and increased risk for postpartum psychiatric illness.
Some, but not all, studies suggest that PMDD is a risk factor for postpartum depression.
Further systematic research on outcomes after postpartum screening is needed to ensure that screening translates into improved clinical outcomes.
This review discusses the novel neurosteroid antidepressant brexanolone for the treatment of postpartum depression.
NPR’s 1A Live hosts an episode focusing on perinatal depression, including information on the new medication zuranolone for the treatment of postpartum depression.
Zuranolone has antidepressant effects in women with severe PPD, observed as early as 3 days after initiation of treatment.
Although new mothers describe breastfeeding as a meaningful and fulfilling aspect of caring for their infants, breastfeeding is also a common source of stress and anxiety. A recent study suggests that difficulties with breastfeeding may [...]
In 2019, brexanolone was introduced by Sage Therapeutics as Zulresso, a novel treatment for postpartum depression. The oral version of this novel antidepressant – SAGE 217 or zuranolone – is now finishing up its Phase [...]
The omega-3 polyunsaturated fatty acids (PUFAs), including eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA), are essential components of the human diet and have a broad range of health benefits. Furthermore, they may also be beneficial [...]
About 15% of women will experience postpartum depression after the birth of a child. While most of those women will have unipolar depression, a certain number of women will have bipolar depression. At this juncture, [...]